Horwitz S, et al. - In ECHELON-2 (a double-blind, double-dummy, randomized, placebo-controlled, active-comparator phase 3 study) from January 24, 2013, to November 7, 2016, authors assessed 601 candidates to estimate the comparative effectiveness and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) vs cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas. They observed similar rates of adverse events in both groups. They also recorded a period of 48.2 months in the A+CHP group and 20.8 months in the CHOP group as the median progression-free survival. Overall, they recommended front-line treatment with A+CHP, a better choice of therapy.